Strong Revenue Growth
Total revenue of $382.5 million, up 13% year-over-year on a GAAP basis and 12.5% on a constant currency basis. Cardiovascular segment sales increased by 10%, and Endoscopy segment sales increased by 81%.
Record Operating Margin
Non-GAAP operating margin increased nearly 109 basis points year-over-year to 21.2%, the highest in any quarter in the company's history as a public company.
Significant Free Cash Flow Increase
Generated $70 million of free cash flow, an increase of 20% year-over-year.
Biolife Acquisition
Acquired Biolife Delaware, L.L.C for $120 million, adding products like StatSeal and WoundSeal, with a potential growth opportunity in a $350 million global addressable market.
New CEO Appointment
Martha Aronson appointed as the new President and Chief Executive Officer effective October 3, 2025.